AVUV vs XBI
Avantis US Small Cap Value ETF vs SPDR S&P Biotech ETF
- • AVUV has the lower expense ratio at 0.25% vs 0.35% for XBI.
- • AVUV pays a higher dividend yield (1.23%).
Side-by-side metrics
| Metric | AVUV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.23% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $32.47B | $10.92B |
YTD return | 21.28% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 1.01 |
P/E ratio | 11.39 | — |
Last price | $122.88 | $156.41 |
Inception | — | — |
Issuer | Avantis | State Street |
AVUV top holdings
| GATX | GATX Corp | 0.96% |
| MATX | Matson Inc | 0.95% |
| SM | SM Energy Co | 0.85% |
| ANF | Abercrombie & Fitch Co Class A | 0.78% |
| VSAT | Viasat Inc | 0.78% |
| CROX | Crocs Inc | 0.77% |
| M | Macy's Inc | 0.77% |
| LYFT | Lyft Inc Class A | 0.76% |
| MUR | Murphy Oil Corp | 0.74% |
| LEA | Lear Corp | 0.71% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About AVUV
AVUV (Avantis US Small Cap Value ETF) is US small-cap value with profitability screen. Managed by Avantis, the fund carries $32.5B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.23%. Its largest holding is GATX Corp (GATX), which represents 1.0% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.